ArticleThe Biochemical journal2026
Modulating backbone flexibility in hydroxamate siderophores for improved iron chelation and peptide nucleic acid delivery into bacteria.
Article in The Biochemical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The development of effective delivery systems for peptide nucleic acids (PNAs) into bacterial cells remains a critical challenge in antisense therapeutics. We report the design and evaluation of hydroxamate siderophore-PNA conjugates that exploit bacterial iron uptake pathways for targeted delivery. We demonstrate that modulating the backbone flexibility of hydroxamate siderophores, through glycine or alanine spacers, enhances iron(III) binding affinity and PNA delivery efficiency into Escherichia coli cells. Molecular dynamics simulations revealed that glycine insertion increases backbone flexibility, enabling optimal coordination of all three hydroxamate groups to iron(III). Circular dichroism spectroscopy and iron(III) competition assays confirmed that the siderophores form stable Λ-configured ferric complexes, with the flexible siderophore showing superior iron(III)-binding affinity compared with the less flexible analog. Growth recovery experiments using E. coli mutants deficient in several transporters indicated recognition and internalization of the siderophores via the TonB-dependent hydroxamate pathway. Molecular docking demonstrated the affinity of these siderophores for E. coli hydroxamate receptors, with binding scores comparable to those of natural siderophores. All three siderophore carriers successfully delivered functional PNA targeting the mrfp reporter gene into bacterial cells, achieving sequence-specific gene silencing as confirmed by fluorescence measurements and confocal microscopy. Additionally, bacteriostatic activity was observed for the best-performing siderophore mimic conjugated with a PNA targeting the essential acpP gene.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.